Speech disturbance and marked decrease in function seen in several older patients on olanzapine

Journal of the American Geriatrics Society

Volumn 46, Issue 10, 1998, Pages 1330-1331

  Gaile, Susan ^a   Noviasky, John A ^a  

^a Monroe Community Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE;

AGED; CASE REPORT; DRUG EFFECT; FEMALE; HUMAN; LETHARGY; LETTER; MALAISE; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; PSYCHIATRIC DIAGNOSIS; RISK ASSESSMENT; SPEECH DISORDER;

EID: 0031694828     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1998.tb04565.x     Document Type: Letter

References (6)

1. Reus VI,. Olanzapine: A novel atypical neuroleptic agent. Lancet 1997; 349: 1264-1265.
2. Tran PV, Dellva MA, Tollefson GD, et al,. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58: 205-211.
3. Fleischhacker WW, Hummer M,. Drug treatment of schizophrenia in the 1990s: Achievements and future possibilities in optimizing outcomes. Drugs 1997; 53: 915-929.
4. Fulton B, Goa KL,. Olanzapine-A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses drugs. 1997; 53: 281-298.
5. Casey DE,. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 (suppl 11): 40-45.
6. Package insert on olanzapine. Indianapolis, IN: Eli Lilly Co.